CG
CGNH.US CardioGenics Holdings Inc
- Market cap
- USD 9.61K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jan 2016.
Is CGNH.US undervalued?
Graham numberThe Graham number of CardioGenics Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CardioGenics Holdings Inc fundamental analysis
No fundamental analysis for CardioGenics Holdings Inc yet.
CardioGenics Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CardioGenics Holdings Inc
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market. Its products include QL Care Analyzer, which is a portable, stand-alone, and automated POC immunoanalyzer; a series of immunoassay tests to enhance the management of patients with cardiovascular diseases; and paramagnetic beads that are used as a solid surface in medical laboratories' immunoassay testing equipment. The company w…
Full company profileCardioGenics Holdings Inc financial statements
2016 annualized: Fiscal year 2016 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jan 31, 2016, the balance sheet is the latest quarter. Figures change when the annual report is published.
CardioGenics Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 167K | 203K | 177K | 21.5K | - | 8.88K | 1.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 81.1K | 130K | 146K | -115K | - | 8.88K | 1.30K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.35M | -1.72M | -1.77M | -16.1M | -1.98M | -3.79M | -1.31M | -2.53M | -974K | -772K | -804K |
| EBITDA | -2.29M | -522K | -1.02M | -28.3M | -2.06M | -5.57M | -1.27M | -2.31M | -952K | -757K | -790K |
| Net Income | -3.64M | -11.8M | -2.83M | -28.9M | -2.02M | -3.87M | -1.31M | -2.92M | -2.68M | -1.92M | -501K |
| EPS | -0.85 | -2.53 | -0.50 | -0.95 | -0.04 | -0.07 | -0.02 | -0.05 | -0.04 | -0.02 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 578K | 134K | 443K | 2.89M | 2.49M | 2.85M | 382K | 548K | 270K | 232K | 558K |
| Total Liabilities | 5.07M | 14.8M | 341K | 923K | 580K | 445K | 889K | 1.46M | 1.42M | 1.79M | 2.34M |
| Shareholders' Equity | -4.50M | -14.6M | 102K | 1.96M | 2.20M | 2.73M | -169K | -561K | -1.16M | -1.56M | -1.79M |
| Cash & Short-term Investments | 451K | 507.00 | 275K | 2.39M | 1.84M | 669K | 27.0K | 312K | 70.7K | 49.9K | 96.8K |
| Total Debt | 2.03M | 2.61M | - | - | 41.9K | 28.3K | 2.63K | 315K | 71.9K | 72.6K | 378K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.19M | -449K | -1.32M | -735K | -2.16M | -1.41M | -971K | -719K | -597K | -607K | 120K |
| Capital Expenditure | 40.9K | 15.6K | 7.25K | 24.1K | 48.1K | 33.0K | 8.03K | 15.8K | 0.00 | 2.06K | 0.00 |
| Free Cash Flow | -2.24M | -464K | -1.33M | -759K | -2.21M | -1.44M | -979K | -734K | -597K | -609K | 120K |
| Ratios | |||||||||||
| ROE | - | - | -2,772.6% | -1,472.8% | -92.1% | -142.1% | - | - | - | - | - |
| ROA | -629.0% | -8,764.6% | -639.1% | -1,001.9% | -81.4% | -135.7% | -342.4% | -532.6% | -992.8% | -826.2% | -89.7% |
| Net Profit Margin | -2,181.8% | -5,792.4% | -1,599.4% | -134,303.3% | - | -43,650.0% | -100,851.9% | - | - | - | - |
| Debt to Equity | - | - | - | - | 0.02x | 0.01x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CardioGenics Holdings Inc dividends
CardioGenics Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Jun 22, 2010.
Who owns CardioGenics Holdings Inc
- Insiders 2.52%
- Institutions 0.00%
- Public & others 97.49%
- Shares outstanding 96.1M
- Free float 99.9M
CardioGenics Holdings Inc company profile
- Company name
- CardioGenics Holdings Inc
- Ticker
- CGNH.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- October
- Address
- 6295 Northam Drive, Mississauga, ON, Canada, L4V 1W8
- Phone
- 905-673-8501
- Website
- cardiogenics.com
About CardioGenics Holdings Inc
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market. Its products include QL Care Analyzer, which is a portable, stand-alone, and automated POC immunoanalyzer; a series of immunoassay tests to enhance the management of patients with cardiovascular diseases; and paramagnetic beads that are used as a solid surface in medical laboratories' immunoassay testing equipment. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was incorporated in 1997 and is based in Mississauga, Canada.
CardioGenics Holdings Inc management
3- Dr. Yahia Abdul Gawad Ch.B., M.D., MB, MSc.Founder, CEO & Director · born 1958
- Mr. James A. Essex CA, MBAChief Financial Officer · born 1949
- Ms. Linda J. Sterling F.Inst.L.C.O.Corporate Secretary & Director · born 1961